Kim George P, Grothey Axel
Division of Hematology/Oncology, Mayo Clinic Jacksonville, FL, USA.
Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S89-97. doi: 10.3816/ccc.2005.s.012.
In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin-containing regimens.
在过去几年中，结直肠癌（CRC）的治疗取得了重大进展。随着伊立替康和奥沙利铂与持续静脉输注5-氟尿嘧啶联合应用，转移性CRC患者的生存时间几乎翻倍。随着针对血管内皮生长因子和表皮生长因子（EGF）通路的生物制剂的加入，晚期转移性疾病患者在缓解率、无进展生存期和总生存期方面有了进一步改善。本文综述了EGF受体抑制剂与含奥沙利铂方案联合应用时对改善CRC患者生存的影响。
